All In Biotech

Drug Trial Radar · NCT00081458

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome

Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

May 25, 2004

Primary completion

Jul 6, 2007

Study completion Jul 6, 2007

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Apr 14, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).

Conditions

  • Short Bowel Syndrome

Interventions

  • PlaceboDrug

    placebo injectable subcutaneously daily into thigh or abdomen

  • Teduglutide 0.05 mg/kg/dDrug

    Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen

  • Teduglutide 0.1 mg/kg/dDrug

    Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A Graded Response Score in Parenteral Nutrition (PN) ReductionTime frame: 6 months

Locations

32 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • Georgetown University

    Washington D.C., District of Columbia

  • Emory University Hospital

    Atlanta, Georgia

  • Northwestern Center for Clinical Research

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Albany Medical Center

    Albany, New York

  • Mount Sinai School of Medicine

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • University of Pennsylvania - Penn Nursing

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • l'Hôpital Erasme

    Brussels, Belgium

  • Royal Alexandra Hospital

    Edmonton, Alberta, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Rigshospitalet, University of Copenhagen

    Copenhagen, Denmark

  • Hôpital Claude-Huriez

    Lille, France

  • Hôpital de la Croix-Rousse

    Lyon, France

  • Hôpital Edouard Herriot

    Lyon, France

  • Hôpital Beaujon

    Paris, France

  • Charité University Hospital

    Berlin, Germany

  • Charité-Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Academic Medical Center

    Amsterdam, Netherlands

  • Pracownia Żywienia Klinicznego

    Olsztyn, Poland

  • Samodzielny Publiczny Szpital Kliniczny-Im.prof W.Orłowskiego CMKP

    Warsaw, Poland

  • St. Mark's Hospital

    Harrow, United Kingdom

  • Hope Hospital

    Salford, Greater Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.